[15-12G] Kezar Life Sciences, Inc. SEC Filing

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 15

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

001-38543

Commission File Number

KEZAR LIFE SCIENCES, INC.

(Exact name of registrant as specified in its charter)

4000 Shoreline Court, Suite 300

South San Francisco, CA 94080

 (650) 822-5600

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Common Stock, $0.001 par value per share

(Title of each class of securities covered by this Form)

None

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

Rule 12g-4(a)(1) ☒

Rule 12g-4(a)(2) ☐

Rule 12h-3(b)(1)(i) ☒

Rule 12h-3(b)(1)(ii) Rule 15d-6 ☐

Rule 15d-22(b) ☐

Approximate number of holders of record as of the certification or notice date: One

Pursuant to the requirements of the Securities Exchange Act of 1934, Kezar Life Sciences, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

Date: May 21, 2026	KEZAR LIFE SCIENCES, INC.
	By:	/s/ Michael Hearne
		Name: Michael Hearne
		Title: Chief Financial Officer